

Experiment Number: 20303 - 06

**P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS
ABRIDGED) (a)**

Date Report Requested: 08/26/2013

Test Type: CHRONIC

Vinylidene chloride

Time Report Requested: 12:08:14

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 75-35-4

First Dose M/F: 06/20/05 / 06/20/05

Species/Strain: MICE/B6C3F1

Lab: BNW

F3_M3

NTP Study Number: C20303
Lock Date: 05/19/2008
Cage Range: ALL
Date Range: ALL
Reasons For Removal: ALL
Removal Date Range: ALL
Treatment Groups: Include ALL
Study Gender: Both
TDMSE Version: 3.0.2.0_001
PWG Approval Date: 07/01/2011

Test Type: CHRONIC

Vinylidene chloride

Time Report Requested: 12:08:14

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 75-35-4

First Dose M/F: 06/20/05 / 06/20/05

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE

Control

6.25 ppm

12.5 ppm

25 ppm

Disposition Summary

	Control	6.25 ppm	12.5 ppm	25 ppm
Animals Initially In Study	50	50	50	50
Early Deaths				
Moribund Sacrifice	12	5	14	19
Natural Death	9	5	4	12
Survivors				
Moribund Sacrifice		1		
Natural Death				1
Terminal Sacrifice	29	39	32	18
Animals Examined Microscopically	50	50	50	50

ALIMENTARY SYSTEM

	Control	6.25 ppm	12.5 ppm	25 ppm
Esophagus	(50)	(50)	(50)	(50)
Gallbladder	(42)	(45)	(47)	(41)
Intestine Large, Cecum	(47)	(48)	(48)	(40)
Carcinoma	1 (2%)			
Intestine Large, Colon	(47)	(48)	(48)	(42)
Intestine Large, Rectum	(48)	(48)	(48)	(42)
Intestine Small, Duodenum	(44)	(47)	(47)	(38)
Adenoma			1 (2%)	
Carcinoma				2 (5%)
Intestine Small, Ileum	(44)	(47)	(47)	(39)
Adenoma	1 (2%)			
Carcinoma		1 (2%)		
Intestine Small, Jejunum	(43)	(47)	(47)	(39)
Carcinoma		2 (4%)		
Hepatocolangiocarcinoma, Metastatic, Liver	1 (2%)			
Liver	(50)	(50)	(50)	(50)
Carcinoma, Metastatic, Testes			1 (2%)	
Hemangioma		1 (2%)	2 (4%)	
Hemangiosarcoma	2 (4%)	2 (4%)	3 (6%)	3 (6%)
Hepatoblastoma	1 (2%)			
Hepatocellular Adenoma	17 (34%)	16 (32%)	16 (32%)	12 (24%)
Hepatocellular Adenoma, Multiple	20 (40%)	19 (38%)	17 (34%)	13 (26%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Vinylidene chloride

Time Report Requested: 12:08:14

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 75-35-4

First Dose M/F: 06/20/05 / 06/20/05

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	Control	6.25 ppm	12.5 ppm	25 ppm
Hepatocellular Carcinoma	18 (36%)	18 (36%)	11 (22%)	21 (42%)
Hepatocellular Carcinoma, Multiple	8 (16%)	1 (2%)	4 (8%)	8 (16%)
Hepatocholangiocarcinoma	1 (2%)	2 (4%)	2 (4%)	3 (6%)
Rhabdomyosarcoma, Metastatic, Skeletal Muscle			1 (2%)	
Sarcoma, Metastatic, Stomach, Glandular Mesentery	(6)	(9)	(6)	1 (2%) (3)
Hepatocellular Carcinoma, Metastatic, Liver				1 (33%)
Hepatocholangiocarcinoma, Metastatic, Liver		1 (11%)		1 (33%)
Pancreas	(50)	(49)	(50)	(48)
Hepatocellular Carcinoma, Metastatic, Liver		1 (2%)		
Hepatocholangiocarcinoma, Metastatic, Liver		1 (2%)		1 (2%)
Rhabdomyosarcoma, Metastatic, Skeletal Muscle			1 (2%)	
Sarcoma, Metastatic, Stomach, Glandular				1 (2%)
Salivary Glands	(50)	(50)	(50)	(50)
Stomach, Forestomach	(49)	(50)	(50)	(49)
Squamous Cell Papilloma	1 (2%)			1 (2%)
Stomach, Glandular	(48)	(49)	(49)	(48)
Hepatocholangiocarcinoma, Metastatic, Liver				1 (2%)
Sarcoma				1 (2%)
Tongue	(0)	(0)	(1)	(0)
Tooth	(2)	(2)	(0)	(1)

CARDIOVASCULAR SYSTEM

Blood Vessel	(0)	(0)	(1)	(3)
Heart	(50)	(50)	(50)	(50)
Carcinoma, Metastatic, Harderian Gland		1 (2%)		
Hepatocellular Carcinoma, Metastatic, Liver	1 (2%)	1 (2%)		
Hepatocholangiocarcinoma, Metastatic, Liver	1 (2%)			

ENDOCRINE SYSTEM

Adrenal Cortex	(50)	(50)	(50)	(50)
----------------	------	------	------	------

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Vinylidene chloride

Time Report Requested: 12:08:14

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 75-35-4

First Dose M/F: 06/20/05 / 06/20/05

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	Control	6.25 ppm	12.5 ppm	25 ppm
Adenoma			1 (2%)	
Carcinoma		1 (2%)		
Sarcoma, Metastatic, Stomach, Glandular				1 (2%)
Capsule, Hepatocholangiocarcinoma, Metastatic, Liver			1 (2%)	
Subcapsular, Adenoma	1 (2%)	1 (2%)	3 (6%)	2 (4%)
Adrenal Medulla	(50)	(50)	(50)	(50)
Pheochromocytoma Benign	1 (2%)	1 (2%)		1 (2%)
Pheochromocytoma Malignant	1 (2%)			
Islets, Pancreatic	(50)	(49)	(49)	(49)
Adenoma	2 (4%)	1 (2%)	1 (2%)	
Hepatocholangiocarcinoma, Metastatic, Liver				1 (2%)
Parathyroid Gland	(26)	(22)	(26)	(24)
Pituitary Gland	(49)	(49)	(50)	(46)
Pars Intermedia, Adenoma	1 (2%)			
Thyroid Gland	(50)	(49)	(50)	(49)
Follicular Cell, Adenoma			1 (2%)	
Follicular Cell, Carcinoma			1 (2%)	

GENERAL BODY SYSTEM

None

GENITAL SYSTEM

Epididymis	(50)	(50)	(50)	(50)
Preputial Gland	(50)	(50)	(50)	(50)
Prostate	(50)	(50)	(50)	(50)
Hepatocellular Carcinoma, Metastatic, Liver		1 (2%)		
Hepatocholangiocarcinoma, Metastatic, Liver				1 (2%)
Seminal Vesicle	(50)	(50)	(50)	(50)
Hepatocholangiocarcinoma, Metastatic, Liver			1 (2%)	
Testes	(50)	(50)	(50)	(50)
Hemangioma	1 (2%)			1 (2%)
Interstitial Cell, Adenoma	1 (2%)	2 (4%)	1 (2%)	1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Vinylidene chloride

Time Report Requested: 12:08:14

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 75-35-4

First Dose M/F: 06/20/05 / 06/20/05

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	Control	6.25 ppm	12.5 ppm	25 ppm
Interstitial Cell, Carcinoma			1 (2%)	
HEMATOPOIETIC SYSTEM				
Bone Marrow	(50)	(50)	(50)	(50)
Hemangioma			1 (2%)	
Hemangiosarcoma	1 (2%)		1 (2%)	2 (4%)
Lymph Node	(2)	(2)	(0)	(2)
Pancreatic, Sarcoma, Metastatic, Stomach, Glandular				1 (50%)
Renal, Hepatocholangiocarcinoma, Metastatic, Liver		1 (50%)		
Lymph Node, Bronchial	(33)	(34)	(31)	(19)
Hepatocholangiocarcinoma, Metastatic, Liver	1 (3%)	1 (3%)		
Lymph Node, Mandibular	(17)	(29)	(19)	(25)
Lymph Node, Mediastinal	(43)	(29)	(43)	(38)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (3%)
Carcinoma, Metastatic, Harderian Gland		1 (3%)		
Hemangiosarcoma			1 (2%)	
Hepatocholangiocarcinoma, Metastatic, Liver	1 (2%)		1 (2%)	1 (3%)
Rhabdomyosarcoma, Metastatic, Skeletal Muscle			1 (2%)	
Lymph Node, Mesenteric	(46)	(48)	(48)	(47)
Carcinoma, Metastatic, Intestine Large, Cecum	1 (2%)			
Carcinoma, Metastatic, Intestine Small, Duodenum				1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver		1 (2%)		1 (2%)
Spleen	(50)	(49)	(50)	(50)
Hemangiosarcoma	2 (4%)	3 (6%)	1 (2%)	4 (8%)
Thymus	(39)	(37)	(38)	(26)
Hemangiosarcoma		1 (3%)		

INTEGUMENTARY SYSTEM

Mammary Gland	(1)	(2)	(0)	(1)
---------------	-----	-----	-----	-----

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Vinylidene chloride

Time Report Requested: 12:08:14

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 75-35-4

First Dose M/F: 06/20/05 / 06/20/05

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	Control	6.25 ppm	12.5 ppm	25 ppm
Skin	(50)	(50)	(50)	(50)
Fibrous Histiocytoma	1 (2%)	2 (4%)	1 (2%)	2 (4%)
Keratoacanthoma	1 (2%)			
Subcutaneous Tissue, Liposarcoma	1 (2%)			
Subcutaneous Tissue, Schwannoma Malignant				1 (2%)

MUSCULOSKELETAL SYSTEM

Bone	(50)	(50)	(50)	(50)
Skeletal Muscle	(1)	(1)	(2)	(2)
Hemangiosarcoma	1 (100%)			1 (50%)
Hepatocholangiocarcinoma, Metastatic, Liver		1 (100%)	1 (50%)	1 (50%)
Rhabdomyosarcoma			1 (50%)	

NERVOUS SYSTEM

Brain	(50)	(50)	(50)	(50)
Carcinoma, Metastatic, Harderian Gland		1 (2%)		

RESPIRATORY SYSTEM

Larynx	(50)	(50)	(50)	(49)
Lung	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Adenoma	7 (14%)	7 (14%)	8 (16%)	7 (14%)
Alveolar/Bronchiolar Adenoma, Multiple		1 (2%)		
Alveolar/Bronchiolar Carcinoma	8 (16%)	8 (16%)	8 (16%)	6 (12%)
Alveolar/Bronchiolar Carcinoma, Multiple	1 (2%)	1 (2%)		
Carcinoma, Metastatic, Harderian Gland		1 (2%)		
Carcinoma, Metastatic, Intestine Small, Duodenum				1 (2%)
Hemangiosarcoma	1 (2%)			
Hepatocellular Carcinoma, Metastatic, Liver	10 (20%)	11 (22%)	8 (16%)	4 (8%)
Hepatocholangiocarcinoma, Metastatic, Liver	1 (2%)	1 (2%)	1 (2%)	2 (4%)
Rhabdomyosarcoma, Metastatic, Skeletal Muscle			1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Vinylidene chloride

Time Report Requested: 12:08:14

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 75-35-4

First Dose M/F: 06/20/05 / 06/20/05

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	Control	6.25 ppm	12.5 ppm	25 ppm
Nose	(50)	(50)	(49)	(49)
Pleura	(1)	(1)	(0)	(0)
Carcinoma, Metastatic, Harderian Gland		1 (100%)		
Hepatocarcinoma, Metastatic, Liver	1 (100%)			
Trachea	(50)	(50)	(50)	(50)
SPECIAL SENSES SYSTEM				
Eye	(50)	(50)	(50)	(48)
Harderian Gland	(50)	(50)	(50)	(50)
Adenoma	7 (14%)	6 (12%)	8 (16%)	8 (16%)
Carcinoma		2 (4%)	1 (2%)	
URINARY SYSTEM				
Kidney	(50)	(50)	(50)	(50)
Hemangiosarcoma	1 (2%)			
Hepatocellular Carcinoma, Metastatic, Liver		1 (2%)		1 (2%)
Hepatocarcinoma, Metastatic, Liver	1 (2%)	1 (2%)	1 (2%)	1 (2%)
Rhabdomyosarcoma, Metastatic, Skeletal Muscle			1 (2%)	
Bilateral, Renal Tubule, Adenoma			1 (2%)	
Bilateral, Renal Tubule, Carcinoma		1 (2%)	7 (14%)	6 (12%)
Bilateral, Renal Tubule, Carcinoma, Multiple			4 (8%)	
Capsule, Sarcoma, Metastatic, Stomach, Glandular				1 (2%)
Renal Tubule, Adenoma		5 (10%)	15 (30%)	10 (20%)
Renal Tubule, Adenoma, Multiple			3 (6%)	
Renal Tubule, Carcinoma		6 (12%)	17 (34%)	12 (24%)
Renal Tubule, Carcinoma, Multiple			3 (6%)	
Urinary Bladder	(50)	(50)	(50)	(49)

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Experiment Number: 20303 - 06

P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)

Date Report Requested: 08/26/2013

Test Type: CHRONIC

Vinylidene chloride

Time Report Requested: 12:08:14

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 75-35-4

First Dose M/F: 06/20/05 / 06/20/05

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	Control	6.25 ppm	12.5 ppm	25 ppm
<hr/>				
SYSTEMIC LESIONS				
Multiple Organ	*(50)	*(50)	*(50)	*(50)
Histiocytic Sarcoma	2 (4%)	1 (2%)	1 (2%)	1 (2%)
Lymphoma Malignant	2 (4%)	2 (4%)	4 (8%)	

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

Vinylidene chloride

Time Report Requested: 12:08:14

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 75-35-4

First Dose M/F: 06/20/05 / 06/20/05

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	Control	6.25 ppm	12.5 ppm	25 ppm
------------------	---------	----------	----------	--------

Tumor Summary for Males

Total Animals with Primary Neoplasms (b)	49	49	49	48
Total Primary Neoplasms	114	114	151	129
Total Animals with Benign Neoplasms	43	41	43	35
Total Benign Neoplasms	61	60	79	56
Total Animals with Malignant Neoplasms	37	38	42	43
Total Malignant Neoplasms	53	54	72	73
Total Animals with Metastatic Neoplasms	11	13	11	7
Total Metastatic Neoplasms	19	28	20	25
Total Animals with Malignant Neoplasms Uncertain Primary Site				
Total Animals with Neoplasms Uncertain- Benign or Malignant				
Total Uncertain Neoplasms				

*** END OF MALE ***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

Test Type: CHRONIC

Vinylidene chloride

Time Report Requested: 12:08:14

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 75-35-4

First Dose M/F: 06/20/05 / 06/20/05

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	Control	6.25 ppm	12.5 ppm	25 ppm
--------------------	---------	----------	----------	--------

Disposition Summary

Animals Initially In Study	50	50	50	50
Early Deaths				
Moribund Sacrifice	11	20	14	17
Natural Death	3	5	6	9
Survivors				
Moribund Sacrifice				1
Terminal Sacrifice	36	25	30	23
Animals Examined Microscopically	50	50	50	50

ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(50)
Gallbladder	(46)	(43)	(45)	(43)
Intestine Large, Cecum	(49)	(48)	(45)	(45)
Carcinoma	1 (2%)			
Hepatocolangiocarcinoma, Metastatic, Liver		1 (2%)		
Sarcoma, Metastatic, Skeletal Muscle			1 (2%)	
Intestine Large, Colon	(49)	(47)	(46)	(46)
Intestine Large, Rectum	(49)	(47)	(47)	(46)
Intestine Small, Duodenum	(49)	(47)	(45)	(46)
Adenoma			1 (2%)	
Hepatocolangiocarcinoma, Metastatic, Liver		1 (2%)		
Intestine Small, Ileum	(49)	(48)	(45)	(45)
Adenoma	1 (2%)			1 (2%)
Carcinoma	1 (2%)	1 (2%)	1 (2%)	3 (7%)
Intestine Small, Jejunum	(48)	(47)	(45)	(45)
Liver	(50)	(50)	(50)	(50)
Fibrosarcoma, Metastatic, Skeletal Muscle				1 (2%)
Hemangioma		1 (2%)		2 (4%)
Hemangiosarcoma	1 (2%)	1 (2%)	1 (2%)	6 (12%)
Hepatocellular Adenoma	13 (26%)	12 (24%)	10 (20%)	12 (24%)
Hepatocellular Adenoma, Multiple	12 (24%)	9 (18%)	26 (52%)	17 (34%)
Hepatocellular Carcinoma	7 (14%)	12 (24%)	10 (20%)	14 (28%)
Hepatocellular Carcinoma, Multiple	1 (2%)	2 (4%)	2 (4%)	3 (6%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Vinylidene chloride

Time Report Requested: 12:08:14

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 75-35-4

First Dose M/F: 06/20/05 / 06/20/05

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	Control	6.25 ppm	12.5 ppm	25 ppm
Hepatocarcinoma		1 (2%)	1 (2%)	2 (4%)
Sarcoma, Metastatic, Skeletal Muscle				1 (2%)
Mesentery	(10)	(16)	(19)	(37)
Hemangiosarcoma			1 (5%)	
Hepatocarcinoma, Metastatic, Liver		1 (6%)		
Sarcoma		1 (6%)	1 (5%)	1 (3%)
Sarcoma, Metastatic, Skeletal Muscle			1 (5%)	1 (3%)
Sarcoma, Metastatic, Uterus				1 (3%)
Pancreas	(50)	(49)	(50)	(50)
Hepatocarcinoma, Metastatic, Liver		1 (2%)		
Sarcoma, Metastatic, Mesentery		1 (2%)	1 (2%)	
Sarcoma, Metastatic, Skeletal Muscle				1 (2%)
Duct, Carcinoma	1 (2%)			
Salivary Glands	(50)	(50)	(50)	(50)
Myxoma	1 (2%)			
Stomach, Forestomach	(50)	(49)	(50)	(50)
Hepatocarcinoma, Metastatic, Liver		1 (2%)		
Sarcoma, Metastatic, Skeletal Muscle				1 (2%)
Squamous Cell Papilloma		3 (6%)	1 (2%)	
Stomach, Glandular	(49)	(48)	(49)	(49)
Carcinoma	1 (2%)			
Sarcoma, Metastatic, Skeletal Muscle			1 (2%)	1 (2%)
Tooth	(0)	(1)	(0)	(0)

CARDIOVASCULAR SYSTEM

Blood Vessel	(0)	(1)	(0)	(0)
Heart	(50)	(50)	(50)	(50)
Hepatocarcinoma, Metastatic, Liver		1 (2%)		
Sarcoma, Metastatic, Mesentery			1 (2%)	

ENDOCRINE SYSTEM

Adrenal Cortex	(50)	(49)	(50)	(49)
Hepatocarcinoma, Metastatic, Liver			1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Vinylidene chloride

Time Report Requested: 12:08:14

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 75-35-4

First Dose M/F: 06/20/05 / 06/20/05

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	Control	6.25 ppm	12.5 ppm	25 ppm
Sarcoma, Metastatic, Skeletal Muscle				1 (2%)
Subcapsular, Adenoma	1 (2%)			
Adrenal Medulla	(50)	(48)	(50)	(49)
Pheochromocytoma Benign	1 (2%)			
Pheochromocytoma Malignant	1 (2%)	1 (2%)		
Islets, Pancreatic	(50)	(49)	(50)	(50)
Adenoma	1 (2%)	1 (2%)	2 (4%)	
Parathyroid Gland	(24)	(22)	(21)	(31)
Pituitary Gland	(50)	(50)	(48)	(47)
Pars Distalis, Adenoma	8 (16%)	5 (10%)	8 (17%)	4 (9%)
Pars Distalis, Carcinoma			1 (2%)	
Thyroid Gland	(50)	(50)	(50)	(50)

GENERAL BODY SYSTEM

None

GENITAL SYSTEM

Clitoral Gland	(45)	(46)	(45)	(45)
Ovary	(50)	(49)	(49)	(49)
Cystadenoma	1 (2%)	3 (6%)	1 (2%)	1 (2%)
Hemangioma			2 (4%)	
Hemangiosarcoma				1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver		1 (2%)		
Luteoma	1 (2%)			
Uterus	(50)	(49)	(50)	(50)
Adenoma				1 (2%)
Hemangioma		1 (2%)		
Hemangiosarcoma	1 (2%)			1 (2%)
Polyp Stromal	2 (4%)	2 (4%)	1 (2%)	3 (6%)
Sarcoma				1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Vinylidene chloride

Time Report Requested: 12:08:14

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 75-35-4

First Dose M/F: 06/20/05 / 06/20/05

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	Control	6.25 ppm	12.5 ppm	25 ppm
HEMATOPOIETIC SYSTEM				
Bone Marrow	(50)	(49)	(50)	(50)
Lymph Node	(8)	(11)	(1)	(8)
Lumbar, Sarcoma, Metastatic, Skeletal Muscle				1 (13%)
Lumbar, Sarcoma, Metastatic, Skin				1 (13%)
Lymph Node, Bronchial	(25)	(38)	(38)	(38)
Hepatocarcinoma, Metastatic, Liver		1 (3%)	1 (3%)	2 (5%)
Myxosarcoma, Metastatic, Skin		1 (3%)		
Lymph Node, Mandibular	(31)	(35)	(30)	(37)
Carcinoma, Metastatic, Harderian Gland				1 (3%)
Lymph Node, Mediastinal	(42)	(45)	(45)	(47)
Carcinoma, Metastatic, Harderian Gland		1 (2%)		
Hemangiosarcoma				1 (2%)
Hepatocarcinoma, Metastatic, Liver		1 (2%)	1 (2%)	1 (2%)
Myxosarcoma, Metastatic, Skin		1 (2%)		
Sarcoma, Metastatic, Mesentery			1 (2%)	
Lymph Node, Mesenteric	(47)	(48)	(47)	(45)
Hepatocarcinoma, Metastatic, Liver		1 (2%)		
Spleen	(50)	(49)	(50)	(49)
Hemangiosarcoma	3 (6%)	3 (6%)	1 (2%)	1 (2%)
Thymus	(47)	(44)	(46)	(40)
Hepatocarcinoma, Metastatic, Liver		1 (2%)		

INTEGUMENTARY SYSTEM

Mammary Gland	(50)	(50)	(50)	(50)
Carcinoma	1 (2%)	1 (2%)	2 (4%)	1 (2%)
Skin	(50)	(50)	(50)	(50)
Fibrous Histiocytoma		2 (4%)	2 (4%)	3 (6%)
Subcutaneous Tissue, Fibrosarcoma	1 (2%)	1 (2%)		
Subcutaneous Tissue, Hemangiosarcoma			1 (2%)	1 (2%)
Subcutaneous Tissue, Myxosarcoma		1 (2%)	1 (2%)	
Subcutaneous Tissue, Sarcoma	1 (2%)	1 (2%)	1 (2%)	3 (6%)
Subcutaneous Tissue, Schwannoma Malignant				1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Vinylidene chloride

Time Report Requested: 12:08:14

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 75-35-4

First Dose M/F: 06/20/05 / 06/20/05

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	Control	6.25 ppm	12.5 ppm	25 ppm
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(50)	(50)
Osteosarcoma				1 (2%)
Skeletal Muscle	(3)	(3)	(2)	(4)
Fibrosarcoma				1 (25%)
Hemangiosarcoma		1 (33%)		
Hepatocholangiocarcinoma, Metastatic, Liver		1 (33%)	1 (50%)	1 (25%)
Sarcoma	1 (33%)		1 (50%)	1 (25%)

NERVOUS SYSTEM

Brain	(50)	(50)	(50)	(50)
Carcinoma, Metastatic, Pituitary Gland			1 (2%)	
Peripheral Nerve	(2)	(2)	(0)	(0)
Spinal Cord	(2)	(2)	(0)	(1)

RESPIRATORY SYSTEM

Larynx	(50)	(50)	(49)	(49)
Lung	(50)	(50)	(50)	(49)
Alveolar/Bronchiolar Adenoma	2 (4%)	4 (8%)	2 (4%)	2 (4%)
Alveolar/Bronchiolar Adenoma, Multiple	1 (2%)			
Alveolar/Bronchiolar Carcinoma	1 (2%)	2 (4%)	6 (12%)	5 (10%)
Alveolar/Bronchiolar Carcinoma, Multiple			1 (2%)	
Carcinoma, Metastatic, Harderian Gland		1 (2%)		1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver	5 (10%)	9 (18%)	3 (6%)	4 (8%)
Hepatocholangiocarcinoma, Metastatic, Liver		1 (2%)	1 (2%)	2 (4%)
Myxosarcoma, Metastatic, Skin		1 (2%)		
Sarcoma, Metastatic, Mesentery			1 (2%)	
Sarcoma, Metastatic, Skin				1 (2%)
Nose	(50)	(50)	(50)	(50)
Carcinoma, Metastatic, Harderian Gland		1 (2%)	1 (2%)	1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Vinylidene chloride

Time Report Requested: 12:08:14

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 75-35-4

First Dose M/F: 06/20/05 / 06/20/05

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	Control	6.25 ppm	12.5 ppm	25 ppm
Trachea	(50)	(50)	(50)	(49)

SPECIAL SENSES SYSTEM

Eye	(50)	(49)	(50)	(49)
Harderian Gland	(50)	(50)	(50)	(48)
Adenoma	1 (2%)	5 (10%)	4 (8%)	1 (2%)
Carcinoma	3 (6%)	2 (4%)	2 (4%)	2 (4%)

URINARY SYSTEM

Kidney	(50)	(50)	(50)	(50)
Sarcoma, Metastatic, Skeletal Muscle				1 (2%)
Renal Tubule, Adenoma				1 (2%)
Urinary Bladder	(49)	(49)	(48)	(48)
Hemangiosarcoma				1 (2%)
Sarcoma, Metastatic, Uterus				1 (2%)

SYSTEMIC LESIONS

Multiple Organ	*(50)	*(50)	*(50)	*(50)
Histiocytic Sarcoma	2 (4%)	2 (4%)	2 (4%)	
Lymphoma Malignant	14 (28%)	20 (40%)	13 (26%)	11 (22%)

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

Vinylidene chloride

Time Report Requested: 12:08:14

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 75-35-4

First Dose M/F: 06/20/05 / 06/20/05

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	Control	6.25 ppm	12.5 ppm	25 ppm
--------------------	---------	----------	----------	--------

Tumor Summary for Females

Total Animals with Primary Neoplasms (b)	45	46	47	47
Total Primary Neoplasms	88	101	109	110
Total Animals with Benign Neoplasms	32	34	38	34
Total Benign Neoplasms	46	46	58	45
Total Animals with Malignant Neoplasms	33	39	36	41
Total Malignant Neoplasms	42	55	51	65
Total Animals with Metastatic Neoplasms	5	14	8	11
Total Metastatic Neoplasms	5	29	17	26
Total Animals with Malignant Neoplasms Uncertain Primary Site				
Total Animals with Neoplasms Uncertain- Benign or Malignant				
Total Uncertain Neoplasms				

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors